载脂蛋白CIII 来源于人血浆

np001132-25μg

25μg

BioReagent

≥95%(SDS-PAGE)

载脂蛋白CIII通过载脂蛋白CII抑制脂蛋白脂肪酶的激活。Apo CIII水平的降低导致从血浆甘油三酯到脂肪组织的脂肪酸摄取增加。因此，载脂蛋白CIII是治疗肥胖症和胰岛素抵抗的潜在靶点。载脂蛋白CIII的正常血浆浓度为每100毫升8-15毫克。 由新鲜、未冷冻的血浆制备，经FDA批准的试验显示，乙型肝炎表面抗原（HBsAg）、抗丙型肝炎病毒（抗 - HCV）、抗乙型肝炎核心抗体（抗 - HBc）均为阴性，且抗人类免疫缺陷病毒 1 型和 2 型（抗 - HIV 1 & 2）也为阴性。 阿拉丁产品是实验室试剂，不得用于人类或用于任何药物目的。仅供研究使用。 Apo CIII inhibits the activation of lipoprotein lipase by Apo CII. Reduced levels of Apo CIII result in higher fatty acid uptake from plasma triglycerides into adipose tissue. Thus, Apo CIII is a potential target for treatment of obesity and insulin resistance. The normal plasma concentration of Apo CIII is 8-15 mg per 100 ml. Prepared from fresh, non-frozen plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests. Aladdin products are laboratory reagents and are not to be administered to humans or used for any drug purpose. For research use only.

Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma. Plays a multifaceted role in triglyceride homeostasis. Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors. Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners . Post-translational: The most abundant glycoforms are characterized by an O-linked disaccharide galactose linked to N-acetylgalactosamine (Gal-GalNAc), further modified with up to 3 sialic acid residues. Less abundant glycoforms are characterized by more complex and fucosylated glycan moieties. O-glycosylated on Thr-94 with a core 1 or possibly core 8 glycan.

天然

8.75 kDa

人(Human)